Who are BW430C (lamotrigine)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lamictal TM, Brand lamotrigine, lamotrigine (generic Teva), Generic lamotrigine, Lamotrigine tablet, Standard dose lamotrigine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bw430c-lamotrigine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BW430C (lamotrigine) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BW430C (lamotrigine) (BW430C (lamotrigine)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Antiepileptic drug. Area: Neurology.

phase 3 Anticonvulsant / Antiepileptic drug Voltage-gated sodium channels; glutamate release inhibition Neurology Small molecule Live · refreshed every 30 min

Target snapshot

BW430C (lamotrigine) (BW430C (lamotrigine)) — GlaxoSmithKline. Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BW430C (lamotrigine) TARGET	BW430C (lamotrigine)	GlaxoSmithKline	phase 3	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels; glutamate release inhibition
Lamictal TM	Lamictal TM	Central Mental Clinic for Outpatients of Baku City	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Brand lamotrigine	Brand lamotrigine	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
lamotrigine (generic Teva)	lamotrigine (generic Teva)	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Generic lamotrigine	Generic lamotrigine	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Lamotrigine tablet	Lamotrigine tablet	Dhaka Medical College	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Standard dose lamotrigine	Standard dose lamotrigine	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Antiepileptic drug class)

Mario Negri Institute for Pharmacological Research · 3 drugs in this class
Eisai Inc. · 2 drugs in this class
Affiliated Hospital of Nantong University · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
MaineHealth · 1 drug in this class
UCB Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BW430C (lamotrigine) — Competitive Intelligence Brief. https://druglandscape.com/ci/bw430c-lamotrigine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing